Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

They offer investors very different value propositions.

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

DexCom is set to report its first-quarter results at month-end, and the Street is expecting a solid double-digit expansion in ...

The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more affordable way to monitor their blood sugar. The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more ...

Dexcom experienced it's largest ever technical glitch over the weekend. The company's technology chief acknowledged that Dexcom needs to do better. Dexcom is analyzing its tech infrastructure and ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...